Literature DB >> 22579597

Identification of host genes showing differential expression profiles with cell-based long-term replication of hepatitis C virus RNA.

Hiroe Sejima1, Kyoko Mori, Yasuo Ariumi, Masanori Ikeda, Nobuyuki Kato.   

Abstract

Persistent hepatitis C virus (HCV) infection frequently causes hepatocellular carcinoma. However, the mechanisms of HCV-associated hepatocarcinogenesis and disease progression are unclear. Although the human hepatoma cell line, HuH-7, has been widely used as the only cell culture system for robust HCV replication, we recently developed new human hepatoma Li23 cell line-derived OL, OL8, OL11, and OL14 cells, in which genome-length HCV RNA (O strain of genotype 1b) efficiently replicates. OL, OL8, OL11, and OL14 cells were cultured for more than 2 years. We prepared cured cells from OL8 and OL11 cells by interferon-γ treatment. The cured cells were also cultured for more than 2 years. cDNA microarray and RT-PCR analyses were performed using total RNAs prepared from these cells. We first selected several hundred highly or moderately expressed probes, the expression levels of which were upregulated or downregulated at ratios of more than 2 or less than 0.5 in each set of compared cells (e.g., parent OL8 cells versus OL8 cells cultured for 2 years). From among these probes, we next selected those whose expression levels commonly changed during a 2-year culture of genome-length HCV RNA-replicating cells, but which did not change during a 2-year culture period in cured cells. We further examined the expression levels of the selected candidate genes by RT-PCR analysis using additional specimens from the cells cultured for 3.5 years. Reproducibility of the RT-PCR analysis using specimens from recultured cells was also confirmed. Finally, we identified 5 upregulated genes and 4 downregulated genes, the expression levels of which were irreversibly altered during 3.5-year replication of HCV RNA. These genes may play roles in the optimization of the environment in HCV RNA replication, or may play key roles in the progression of HCV-associated hepatic diseases.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579597     DOI: 10.1016/j.virusres.2012.04.008

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  5 in total

1.  Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities.

Authors:  Weilin Gu; Youki Ueda; Hiromichi Dansako; Shinya Satoh; Nobuyuki Kato
Journal:  FASEB Bioadv       Date:  2021-03-04

2.  Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.

Authors:  Shinya Satoh; Kyoko Mori; Youki Ueda; Hiroe Sejima; Hiromichi Dansako; Masanori Ikeda; Nobuyuki Kato
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

3.  Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.

Authors:  Ana Claudia Silva Braga; Bruno Moreira Carneiro; Mariana Nogueira Batista; Mônica Mayumi Akinaga; Cíntia Bittar; Paula Rahal
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

4.  Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor α.

Authors:  Shinya Satoh; Kyoko Mori; Daichi Onomura; Youki Ueda; Hiromichi Dansako; Masao Honda; Shuichi Kaneko; Masanori Ikeda; Nobuyuki Kato
Journal:  Hepatol Commun       Date:  2017-07-13

5.  Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems.

Authors:  Nobuyuki Kato; Hiroe Sejima; Youki Ueda; Kyoko Mori; Shinya Satoh; Hiromichi Dansako; Masanori Ikeda
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.